The Centers for Medicare & Medicaid Services announced that enforcement actions have halted more than $1.6 billion in potentially fraudulent Medicare laboratory payments and revoked 157 laboratory providers from the program since the start of the current administration, on Aug. 28.
CMS described the action as the largest announced Medicare lab fraud enforcement effort in recent memory. The revocations remove the identified providers from the Medicare program entirely, barring them from submitting future claims.
The scale of the fraud — $1.6 billion in improper payments from a single category of provider — reveals systemic vulnerabilities in how CMS oversees laboratory billing. Medicare’s clinical laboratory benefit covers diagnostic testing for the program’s roughly 65 million beneficiaries, making it a high-volume, high-value target for fraudulent billing schemes.
For taxpayers, every dollar lost to Medicare fraud increases the financial pressure on a program already facing long-term solvency challenges. The Medicare Trust Fund’s projected depletion date has been a recurring concern for Congress and the program’s trustees.
CMS did not specify which laboratories were revoked or the geographic distribution of the fraud in its initial announcement. Lab fraud schemes have historically been concentrated in states with large Medicare populations, including Florida, Texas, California and New York.
Common Medicare lab fraud schemes include billing for tests never performed, ordering medically unnecessary tests and using patient information harvested through telemarketing operations to generate fake orders. The revoked providers are expected to face additional civil and potentially criminal proceedings from the Department of Justice and the HHS Office of Inspector General.
Medicare beneficiaries whose claims were processed through revoked laboratories may need to verify that their medical records accurately reflect tests actually performed, CMS said.
The enforcement campaign is expected to continue, with CMS indicating it is actively investigating additional providers.